PRKN and small cell lung carcinoma: Moreover, METTL3 enhanced chemotherapy resistance in small cell lung cancer (SCLC) by activating the Pink1–Parkin mitophagy pathway and exacerbating mitochondrial damage through DCP2 targeting (21).